Pfizer Secures Rights to Exubera® from Sanofi-Aventis
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 68 (Table of Contents)
Published: 6 Feb-2006
DOI: 10.3833/pdr.v2006.i68.561 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer and Sanofi-Aventis entered into license agreement to acquire worldwide rights to Exubera® (human insulin [rDNA orgin]) inhalation powder for treating diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018